<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01776164</url>
  </required_header>
  <id_info>
    <org_study_id>1210M22281</org_study_id>
    <nct_id>NCT01776164</nct_id>
  </id_info>
  <brief_title>Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia</brief_title>
  <official_title>Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bob Allison Ataxia Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Friedreich's ataxia is characterized by progressive alterations in the function of the&#xD;
      cerebellum accompanied by an atrophy of the spinal cord. Although the genetic defect&#xD;
      responsible for the disease has been identified more than 15 years ago, objective markers of&#xD;
      the pathologic process (i.e., biomarkers) that would allow measuring the effects of potential&#xD;
      therapies are still lacking. Moreover, it is still unclear how the malfunction of the&#xD;
      cerebellum affects the rest of the brain, and understanding the connectivity and&#xD;
      neurochemistry of the central nervous system might yield new insights in the understanding of&#xD;
      the disease, in addition to providing potential markers.&#xD;
&#xD;
      To address these needs, the investigators aim at utilizing the capabilities of Magnetic&#xD;
      Resonance Imaging (MRI) and Spectroscopy (MRS). Using techniques called Diffusion Imaging,&#xD;
      resting-state functional MRI, and Proton Spectroscopy (1H MRS), the investigators propose to&#xD;
      determine the differences in the connectivity and neurochemistry of the spinal cord and the&#xD;
      brain between patients affected by Friedreich's ataxia and healthy controls. The&#xD;
      investigators plan on imaging both patients and control subjects using a 3T magnet, a system&#xD;
      that although not yet available in all medical facilities, is becoming standard in most&#xD;
      hospitals and clinics. The first aim is to scan patients already scanned last year (12-month&#xD;
      follow-up). The second aim is to scan patients at an early stage of the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in connectivity (apparent coefficient of diffusion, fractional anisotropy, radial and axial diffusivity), anatomy (cortical thickness, volumetry analysis) and biochemistry (metabolite concentrations) between patients and controls</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators will look at the differences between patients and controls. This is observational, not interventional.&#xD;
The fractional anisotropy (FA) is a scalar value. The apparent coefficient of diffusion, radial and axial diffusivity are measured in mm2/s. The metabolite concentrations in the brain are in the order of Âµg/ g wet tissue weight. Cortical thickness is measured in mm.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Patient with FRDA</arm_group_label>
    <description>Patients affected by Friedreich's ataxia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy volunteers age- and gender-matched with no neurological disease identified.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Friedreich's ataxia at the early stage of the disease (e.g. ambulatory and&#xD;
        not wheelchair bound and no to early cardiomyopathy) Age- and gender-matched healthy&#xD;
        volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetic diagnosis of Friedreich's ataxia for patient volunteers with GAA repeat&#xD;
             expansion number&#xD;
&#xD;
          -  Absence of neurological conditions for control volunteers&#xD;
&#xD;
          -  Control volunteers will be age-, race-, and gender-matched to the patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Weight over 300 lbs&#xD;
&#xD;
          -  Presence of a pacemaker or any paramagnetic object in the body&#xD;
&#xD;
          -  Severe scoliosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Gilles Henry, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Lenglet, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich</keyword>
  <keyword>ataxia</keyword>
  <keyword>FRDA</keyword>
  <keyword>FA</keyword>
  <keyword>recessive</keyword>
  <keyword>neurodegenerative</keyword>
  <keyword>cerebellum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

